Down Syndrome – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Down Syndrome is a chromosomal disease
characterized by intellectual disability, a distinctive facial appearance, and
low muscle tone (hypotonia) in infancy. Although all affected people experience
cognitive delays, the intellectual disability is usually mild to moderate.
People with DS may have a variety of congenital disabilities. A heart defect
affects approximately half of all affected children. Digestive abnormalities,
such as intestine blockage, are less common. Individuals with DS are at a
higher risk of developing various medical conditions. These include
gastroesophageal reflux, a backflow of acidic stomach contents into the
esophagus, celiac disease, and gluten intolerance. Trisomy 21 (nondisjunction)
is the most ordinary type of Down syndrome, accounting for 95 percent of cases.
Babies are typically born with 23 chromosome pairs (or 46 total chromosomes) in
each cell, one inherited from the mother and father. In Trisomy 21, an error in
cell division is called “nondisjunction” this results in a baby being born with
an additional copy of chromosome 21, meaning there are three copies of
chromosome 21 instead of the usual two.
The prevalence of Down Syndrome ranges
from 80 to 91 cases per 100,000 population in the USA.
The competitive
landscape of Down Syndrome includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs insights of Down
Syndrome across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Down
Syndrome Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 Donepezil HCl Eisai
Inc. Phase 2
2 ELND005 Elan Pharmaceuticals Phase 2
3 RG1662 Hoffmann-La
Roche Phase 2
Comments
Post a Comment